FitLife Brands posts Q4 revenue surge to $25.9M after Irwin acquisition; Q4 adjusted EBITDA $3.5M

FitLife Brands reported a significant increase in its fourth-quarter revenue, reaching $25.9 million, primarily due to the acquisition of Irwin. The company also posted a Q4 adjusted EBITDA of $3.5 million, marking a 14% year-over-year increase. While legacy FitLife organic revenue grew for the year, Q4 legacy revenue saw a decline.

Original reporting
Published Apr 8, 2026, 12:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 8, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FTLF
Bullish
medium confidence
Mentioned
$FTLF
Relevance
6/10
AlphAI data visualization · based on TradingView
Decision brief

The 30-second read

$FTLFBullishMed
01

Why it matters

The acquisition appears to have positively impacted revenue and EBITDA, but the decline in legacy revenue warrants caution.

02

Market read

The news is relevant for investors interested in the consumer health sector, indicating potential growth opportunities.

03

What to watch

Integration costs and market competition may dampen the long-term benefits of the acquisition.

Relevance 6/10Timing: Immediate, as earnings and acquisition details are recent.

Background

FitLife Brands acquired Irwin, a strategic move to expand product offerings and market share, leading to a revenue surge in Q4.

Company-level read

Ticker impact

$FTLFBullishMedium confidence
Context

The news highlights a revenue increase primarily driven by an acquisition, with a modest organic growth. The positive earnings report and acquisition activity suggest potential short- to medium-term bullishness.

Expected impact

Moderate upward movement in the near term, with potential for continued growth if acquisition benefits are realized.

Evidence & confidence

The revenue boost and EBITDA growth support a bullish outlook, but the decline in legacy revenue introduces some caution. The overall sentiment remains positive, but the sustainability depends on integration success and organic growth recovery.

Market effects

Potential positive sentiment in the consumer health and wellness sector due to acquisition and revenue growth.

Limited regional impact; primarily relevant to North American markets where FitLife operates.

Low; company-specific news with limited global implications.

Counterpoint

The decline in legacy revenue could signal underlying challenges, risking future profitability.

Key entities

  • FitLife Brands

    A health and wellness product company.

  • Irwin

    A company acquired to expand FitLife's product portfolio.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FitLife Brands Announces Second Quarter 2026 Results

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$UALMed

United Airlines system outage disrupts departures, 418 flights delayed

United Airlines experienced a system outage causing 418 flight delays. The issue affected departing flights and pilot applications, but not in-air flights or United Express services. The airline resolved the outage, attributing it to a technology issue, not cybersecurity. Recent U.S. tech disruptions include JPMorgan Chase's banking service delays and an FAA air traffic control system malfunction.

$BAMed

First permanently assigned F-15EXs touch down at Kadena Air Base

Kadena Air Base in Japan received two permanently assigned F-15EX Eagle II fighter jets, marking the first overseas U.S. base to do so. The Air Force aims to boost airpower in the Pacific, replacing older F-15C/D models. The jets, with advanced avionics and weapons capacity, will support operations with Japan and regional partners. Boeing received a $2.38 billion contract for 22 more F-15EXs, increasing the total to 120.